CD8A and leukemia: To demonstrate the therapeutic potential of bAC CARTs, we transfected activated CD8+ T cells with anti-human CD19 (hCD19) mRNA and assessed the function of the resulting anti-hCD19 CAR-T cells by co-culturing with Nalm6-GL, a B-cell precursor leukemia cell line that stably express GFP and firefly luciferase (Fig. 4b).